Usually not solely to prevent rejection. Conventional, culture-expanded donor mesenchymal stromal cells (MSCs) have often been given without donor–recipient HLA matching or a dedicated anti-rejection drug regimen. That is a feature of particular treatment protocols, not a rule that applies to every donor-cell product or patient.PMC6888380
MSCs are not invisible to the immune system. They can provoke donor-directed immune responses, and the consequences for treatment effectiveness are not fully understood.PMC4320647 If your plan includes steroids or another immune-suppressing medicine, ask what it is for: your underlying disease, transplant care, an infusion reaction precaution, or protection of the administered cells. Those are different reasons.

Are Donor MSCs the Same as a Stem Cell Transplant?
No. Allogeneic means donor-derived; autologous means your own cells. Neither word identifies the cell type. Blood-forming stem cell transplantation restores blood-cell production after conditioning treatment and involves donor matching and transplant-specific risks. It should not be confused with an MSC infusion or local injection.Stem cell transplant
HLA matching compares immune-recognition markers between donor and recipient. Immunosuppression means reducing immune activity with medicines such as corticosteroids or tacrolimus. An MSC protocol can omit matching without proving that immune recognition is impossible, or that no other medication is needed.PMC6888380
Why Can MSCs Be Given Without Anti-Rejection Drugs?
Culture-expanded MSCs typically express relatively low levels of HLA class I and little or no HLA class II under resting conditions. They also generally lack several signals needed for strong T-cell activation. Their ability to modulate immune responses helps explain why unmatched donor MSCs have been investigated without the anti-rejection regimens used for organ transplants.PMC6888380
These properties vary with the cell preparation and inflammatory environment. Low immunogenicity is not permanent immune tolerance. Laboratory and animal findings show immune recognition and clearance, while human studies have detected donor-specific antibodies. Neither the absence of immediate symptoms nor omission of HLA matching establishes that the cells persist, work, or cannot cause sensitization.PMC4320647
What Have Human Studies Found?
The useful question is whether the evidence matches the proposed cell source, disease, route, and dosing schedule. These studies illustrate why “no routine matching” should not become “no immune risk.”
| Study setting | What was assessed | What it means |
|---|---|---|
| Knee osteoarthritis and degenerative disc disease; donor bone marrow MSCs delivered locally in two trials | An immune substudy included 23 recipients in its HLA analysis. Donor-specific antibodies were detected in 2 of 13 assessed knee patients, with reactivity decreasing over time, and in none of 9 tested disc patients. | Closer HLA matching was not associated with better pain outcomes in this small analysis. It was not a trial of matching strategies or immunosuppression, and its single-dose findings do not establish repeat-dose safety.PMC5585421 |
| Moderate-to-severe COPD; randomized, double-blind, placebo-controlled US trial | 62 people were randomized: 30 to non-HLA-matched donor MSCs and 32 to placebo. The MSC group received 100 million cells intravenously on days 0, 30, 60, and 90. Follow-up was planned for two years. | No infusion toxicities or deaths or serious adverse events judged related to MSC administration were reported. There was no significant improvement over placebo in lung function or quality-of-life measures. Background medication use was not necessarily absent.PMC4694112 |
The orthopedic report explicitly called for more research on sensitization with multiple doses. The COPD trial provides repeat-infusion safety observations for one product and population, not proof that all repeat-dose MSC protocols are safe or that donor-specific antibodies never develop.PMC5585421PMC4694112
Why Might an MSC Patient Still Receive Immune Drugs?
Treatment of GVHD or Another Existing Condition
Acute graft-versus-host disease (GVHD) after a blood stem cell transplant is not the same problem as rejection of an MSC dose. Japan’s TEMCELL is a donor bone marrow MSC product approved for acute GVHD following hematopoietic stem cell transplantation. Its PMDA review describes continuation of existing transplant medicines under specified trial conditions. This does not show that an additional anti-rejection regimen was required specifically to protect TEMCELL.000215658.pdf
In the United States, RYONCIL was approved in December 2024 for steroid-refractory acute GVHD in children aged 2 months and older. In the single-arm study of 54 treated children, 38 (70%) had an overall response at day 28, including 16 (30%) with a complete response. These were children with serious post-transplant disease, not otherwise healthy adults receiving elective MSC infusions.Download
If you already take immune-suppressing medicines for GVHD, an organ transplant, or another illness, do not stop or taper them because an MSC protocol says “no immunosuppression required.” Your treating specialist must reconcile the two plans.
Premedication Before an Infusion
A steroid dose before an infusion is not automatically long-term anti-rejection treatment. For example, the RYONCIL prescribing information directs premedication with corticosteroids and antihistamines because of hypersensitivity and acute infusion reactions. Its warnings also include transmission of infectious agents and ectopic tissue formation.Download
A Different Cell Product or Protocol
A donor-derived product is not necessarily an MSC product. Do not transfer an MSC protocol’s medication rules to blood-forming stem cells or another donor-cell intervention. Likewise, repeat dosing or surgical delivery does not by itself establish that immunosuppression is required. Ask for the exact protocol’s rationale rather than treating the route or donor label as the answer.
Does Avoiding Immunosuppression Mean the Treatment Works?
Not needing a dedicated anti-rejection regimen is not evidence of clinical benefit, and it does not make a cell procedure risk-free.
In the COPD trial, 10 of 30 MSC recipients experienced serious adverse events during follow-up, although none was judged related to MSC administration. Only 19 of 30 MSC recipients completed the full two-year protocol. These details matter when interpreting a reassuring infusion-safety summary.PMC4694112
A separate example is Alofisel, a donor adipose-derived MSC product previously authorized in the EU for complex perianal fistulas in adults with Crohn’s disease. Its 568-patient confirmatory study did not meet the primary endpoint: combined remission at 24 weeks was 48.76% with Alofisel versus 46.32% with placebo (p=0.571). EMA announced its EU market withdrawal in December 2024. No new safety signals were identified; the problem was failure to confirm benefit. That outcome concerns this product and indication, not every MSC therapy.Alofisel withdrawn eu market
How Should You Check a Japanese Treatment Offer?
Ask whether the proposal concerns an approved regenerative medical product used for its authorized indication, a clinical trial, or care provided under a filed regenerative medicine plan. Japan’s regenerative medicine framework includes separate rules for medical provision and cell processing. A filed plan is not equivalent to marketing authorization for a product, and filing alone does not establish that the advertised treatment is effective.Index
TEMCELL’s GVHD indication does not authorize a different clinic’s donor MSCs for knee pain, anti-aging, or an “immune reset.”000215658.pdf Request the product or plan identifier and the written protocol. For the cell-processing and release documentation, ask what donor screening, identity, sterility, storage, and transport checks apply to your batch. A manufacturing explanation cannot substitute for evidence of benefit.
How to Read Your Medication Plan
If a proposed plan says “no immunosuppression” but lists a steroid, ask the prescriber to identify its purpose, dose, timing, and duration. The RYONCIL label provides a concrete example of corticosteroid premedication for infusion precautions; that is different from maintaining immune suppression to prevent graft rejection.Download A drug name alone cannot settle the question.
Bring the actual medication list and protocol to your consultation. Ask:
- What exact cell type, donor source, product, dose, and administration route are proposed?
- Is this use approved for my condition and age group, experimental, or offered under a filed treatment plan?
- Is each immune-active medicine for my existing disease, infusion precautions, or the administered cells? What is the planned duration?
- If no anti-rejection medicine is planned, what human evidence supports that choice for this product and schedule?
- Would my transplant history, prior transfusions, pregnancy history, or planned repeat doses change the need for antibody testing or follow-up?
- Which adverse events will be monitored, who handles urgent complications, and how will follow-up work after I return home?
- What established alternatives are available, and which measurable outcome would justify continuing treatment?
This checklist helps organize a consultation; it cannot determine whether you personally need immunosuppression or whether an MSC intervention is appropriate. That requires a clinician who has your medical history and the exact protocol.
Have questions about a proposed donor-cell protocol?
Ask which records are needed for a consultation. Include the product name, medication list, and written treatment plan.
Bottom Line
Allogeneic MSCs often do not require a dedicated anti-rejection regimen, but “donor-derived” does not determine your medication needs. Separate protection of the administered cells from treatment of your underlying illness and infusion premedication. Verify the exact product, indication, schedule, and reason for each medicine before agreeing to treatment—and do not change an existing prescription on your own.
Sources
- Kot M, et al. The Importance of HLA Assessment in “Off-the-Shelf” Allogeneic Mesenchymal Stem Cells Based-Therapies. International Journal of Molecular Sciences. 2019. Review of HLA biology and clinical practice, not proof of efficacy.
- Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nature Biotechnology. 2014;32:252–260. Perspective covering human and preclinical evidence.
- National Cancer Institute. Stem Cell Transplants in Cancer Treatment. Blood-forming stem cell transplantation and donor matching.
- García-Sancho J, et al. Influence of HLA Matching on the Efficacy of Allogeneic Mesenchymal Stromal Cell Therapies for Osteoarthritis and Degenerative Disc Disease. Transplantation Direct. 2017;3:e205. Small immune substudy of two clinical trials.
- Weiss DJ, et al. A Placebo-Controlled, Randomized Trial of Mesenchymal Stem Cells in COPD. Chest. 2013;143:1590–1598. US randomized trial.
- PMDA. TEMCELL review report. Japan, 2015. Approved indication, clinical studies, and concomitant medication restrictions.
- FDA. RYONCIL prescribing information. Initial US approval, December 2024. Indication, clinical results, premedication, and warnings. See also the FDA approval summary.
- EMA. Alofisel withdrawn from the EU market. December 13, 2024. Confirmatory study results and EU withdrawal.
- MHLW. Regenerative medicine, cell therapy, and gene therapy. Japan’s provision, research, and manufacturing framework.




